Jpmorgan Chase & CO Bellus Health Inc. Transaction History

Jpmorgan Chase & CO

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 11, 2023	BUY	$7.14 - $8.53 $427,357 - $510,554	59,854 Added 16.69%	418,416 $3.01 Million
Q4 2022 Feb 13, 2023	SELL	$8.22 - $10.76 $1.42 Million - $1.86 Million	-173,017 Reduced 32.55%	358,562 $2.95 Million
Q3 2022 Nov 14, 2022	SELL	$8.95 - $12.0 $3.45 Million - $4.62 Million	-385,336 Reduced 42.03%	531,579 $5.61 Million
Q2 2022 Aug 11, 2022	SELL	$6.46 - $10.02 $1.57 Million - $2.43 Million	-242,818 Reduced 20.94%	916,915 $8.47 Million
Q1 2022 May 11, 2022	BUY	$5.56 - $7.99 $3.6 Million - $5.18 Million	648,068 Added 126.66%	1,159,733 $7.98 Million
Q4 2021 Feb 10, 2022	SELL	$5.26 - $8.3 $2.36 Million - $3.72 Million	-447,761 Reduced 46.67%	511,665 $4.12 Million
Q3 2021 Nov 12, 2021	BUY	$2.7 - $6.64 $2.59 Million - $6.37 Million	959,426 New	959,426 $5.89 Million

128K

Ticker BLU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 125,793,000
Description
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. Th...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.